Protocol No. CKAE609X2201 A proof-of-concept open label, 3-day repeated dose study to assess efficacy, safety, tolerability and pharmacokinetics of KAE609 in adult patients with acute, uncomplicated Plasmodium falciparum or vivax malaria mono-infection
Tools
Leong, Franz Joel Wen, Lefevre, Gilbert and Magnusson, Baldur (2014) Protocol No. CKAE609X2201 A proof-of-concept open label, 3-day repeated dose study to assess efficacy, safety, tolerability and pharmacokinetics of KAE609 in adult patients with acute, uncomplicated Plasmodium falciparum or vivax malaria mono-infection. New England Journal of Medicine.
Abstract
Not applicable.
This is a redacted protocol for inclusion in the online supplementary materials accompanying the manuscript entitled 'The novel spiroindolone KAE609 clears parasitemia rapidly in Falciparum and Vivax malaria'
Item Type: | Article |
---|---|
Date Deposited: | 13 Oct 2015 13:13 |
Last Modified: | 13 Oct 2015 13:13 |
URI: | https://oak.novartis.com/id/eprint/21205 |